Steris PLC (NYSE:STE) – Stock analysts at Northcoast Research upped their FY2019 earnings per share (EPS) estimates for Steris in a report released on Wednesday, November 7th. Northcoast Research analyst D. Keiser now expects that the medical equipment provider will post earnings of $4.79 per share for the year, up from their prior forecast of $4.74. Northcoast Research also issued estimates for Steris’ Q4 2019 earnings at $1.39 EPS, Q1 2020 earnings at $1.09 EPS, Q2 2020 earnings at $1.22 EPS and Q4 2020 earnings at $1.53 EPS.
Steris (NYSE:STE) last announced its quarterly earnings data on Tuesday, November 6th. The medical equipment provider reported $1.10 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.08 by $0.02. The firm had revenue of $679.00 million during the quarter, compared to analyst estimates of $659.14 million. Steris had a net margin of 11.72% and a return on equity of 12.15%. The business’s quarterly revenue was up 7.1% on a year-over-year basis. During the same period in the previous year, the business posted $0.94 EPS.
Other equities research analysts have also issued reports about the stock. Zacks Investment Research lowered shares of Steris from a “buy” rating to a “hold” rating in a report on Tuesday, July 24th. Stephens reiterated a “buy” rating and set a $125.00 price target on shares of Steris in a report on Thursday, August 9th. KeyCorp upped their price target on shares of Steris from $115.00 to $120.00 and gave the company an “overweight” rating in a report on Thursday, August 9th. Finally, JMP Securities upped their price target on shares of Steris from $113.00 to $125.00 and gave the company a “market outperform” rating in a report on Thursday, August 9th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $115.00.
Shares of STE opened at $120.35 on Friday. The company has a market capitalization of $10.13 billion, a PE ratio of 29.00 and a beta of 1.03. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.63 and a quick ratio of 2.02. Steris has a fifty-two week low of $82.88 and a fifty-two week high of $121.67.
A number of hedge funds and other institutional investors have recently modified their holdings of STE. Guggenheim Capital LLC raised its holdings in Steris by 41.3% in the 1st quarter. Guggenheim Capital LLC now owns 16,767 shares of the medical equipment provider’s stock worth $1,565,000 after purchasing an additional 4,897 shares in the last quarter. Allianz Asset Management GmbH raised its holdings in Steris by 47.3% in the 1st quarter. Allianz Asset Management GmbH now owns 138,158 shares of the medical equipment provider’s stock worth $12,898,000 after purchasing an additional 44,358 shares in the last quarter. Clinton Group Inc. bought a new position in Steris in the 2nd quarter worth $301,000. State of Alaska Department of Revenue raised its holdings in Steris by 40.0% in the 2nd quarter. State of Alaska Department of Revenue now owns 9,200 shares of the medical equipment provider’s stock worth $966,000 after purchasing an additional 2,630 shares in the last quarter. Finally, Addenda Capital Inc. raised its holdings in Steris by 116.1% in the 2nd quarter. Addenda Capital Inc. now owns 19,306 shares of the medical equipment provider’s stock worth $1,749,000 after purchasing an additional 10,371 shares in the last quarter. Institutional investors and hedge funds own 89.52% of the company’s stock.
In other Steris news, CEO Walter M. Rosebrough, Jr. sold 10,000 shares of the company’s stock in a transaction on Wednesday, November 7th. The shares were sold at an average price of $120.50, for a total value of $1,205,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Michael J. Tokich sold 34,500 shares of the company’s stock in a transaction on Wednesday, November 7th. The stock was sold at an average price of $119.16, for a total transaction of $4,111,020.00. Following the completion of the transaction, the insider now owns 64,958 shares of the company’s stock, valued at $7,740,395.28. The disclosure for this sale can be found here. Insiders have sold a total of 45,800 shares of company stock valued at $5,464,727 over the last quarter. 2.38% of the stock is currently owned by company insiders.
STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.
See Also: Fundamental Analysis and Individual Investors
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.